Salix Pharmaceuticals Company Overview

Salix Pharmaceuticals was a biopharmaceutical company that focused on developing and commercializing gastrointestinal (GI) treatments.

The company was founded in 1991 and was headquartered in Raleigh, North Carolina.

Salix Pharmaceuticals was acquired by Valeant Pharmaceuticals in 2015 for $11.2 billion.

This acquisition marked a significant milestone for Salix, bringing new resources and expertise to the table.

Salix Pharmaceuticals' business operations were marked by a strong focus on the development and commercialization of products for gastroenterology and hepatology.

The company's headquarters was located in Raleigh, North Carolina, and it had a significant presence in the United States and Europe.

Salix Pharmaceuticals had a diverse portfolio of products, including Xifaxan, which was used to treat irritable bowel syndrome with diarrhea.

Salix Pharmaceuticals is based in Bridgewater, New Jersey.

Knowing a company's location can be helpful for understanding their business operations and logistics.

674 people are employed at Salix Pharmaceuticals. This number suggests a relatively small yet focused workforce.

At Salix Pharmaceuticals, leadership is in the hands of experienced professionals. Carolyn Logan is the CEO of Salix Pharmaceuticals.

The company has a strong leadership team that helps drive its success. Carolyn Logan's leadership has been instrumental in shaping the company's direction and vision.

With Carolyn Logan at the helm, Salix Pharmaceuticals is well-positioned for continued growth and innovation.

Salix Pharmaceuticals has a notable acquisition history. Bausch Health acquired Salix Pharmaceuticals in 2015.

This acquisition was a significant milestone for Bausch Health, marking its largest disclosed transaction. The deal value was a staggering 14.5B USD.

Bausch Health has a history of making strategic acquisitions in the Life Science sector. This acquisition was its 17th transaction in the sector, and its 16th in the United States.

The acquisition was also a notable expansion for Bausch Health into the North Carolina market. This was its first transaction in the state.

Here are the key facts about the acquisition:

Salix Pharmaceuticals has been making waves in the industry with some exciting updates.

The company has been working on expanding its product portfolio, which now includes products like Xifaxan for irritable bowel syndrome with diarrhea (IBS-D) and Apriso for moderate to severe ulcerative colitis.

In 2015, Salix Pharmaceuticals was acquired by Valeant Pharmaceuticals International, marking a significant shift in the company's direction.

The acquisition brought new resources and expertise to the table, allowing Salix to focus on developing new treatments for gastrointestinal disorders.

Xifaxan has been a game-changer for patients with IBS-D, offering a new treatment option that can help alleviate symptoms and improve quality of life.

Apriso has also been a valuable addition to the Salix portfolio, providing a treatment option for patients with moderate to severe ulcerative colitis.

The company's commitment to innovation and patient care has earned it a reputation as a leader in the industry.

Salix Pharmaceuticals continues to work towards developing new treatments and improving existing ones, with a focus on making a positive impact on patients' lives.

Broaden your view: Focus Financial Partners

Salix Pharmaceuticals is classified under the SIC codes 28 and 283, indicating its primary focus on pharmaceuticals.

The company is a subsidiary of Bausch Health and operates in the pharmaceutical industry, which is its core business.

Salix Pharmaceuticals is based in Bridgewater, New Jersey, and has been in operation since 1989, when it was founded by Randy W. Hamilton and Lorin K. Johnson.

Here are the SIC codes for Salix Pharmaceuticals:

The company's headquarters is located in Bridgewater, New Jersey, and it has been a subsidiary of Bausch Health since its acquisition in 2015.